Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis

Allergol Int. 2019 Oct;68(4):539-540. doi: 10.1016/j.alit.2019.04.006. Epub 2019 May 9.

Authors

Kenchi Takenaka¹, Tomoko Minami², Yoko Yoshihashi², Shinya Hirata³, Yoshitaka Kimura⁴, Hajime Kono⁴

Affiliations

¹ Jinai Clinic, Internal Medicine, Saitama, Japan. Electronic address: takenaka.rheu@gmail.com.
² Jinai Clinic, Internal Medicine, Saitama, Japan.
³ Department of Clinical Rheumatology, Kumamoto University Graduate School of Medicine, Kumamoto, Japan.
⁴ Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

PMID: 31080020
DOI: 10.1016/j.alit.2019.04.006

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anti-Asthmatic Agents
Antibodies / blood*
Antibodies, Antineutrophil Cytoplasmic / immunology*
Antibodies, Monoclonal, Humanized / therapeutic use*
Eosinophilia / blood
Eosinophilia / drug therapy*
Eosinophilia / immunology
Granulomatosis with Polyangiitis / blood
Granulomatosis with Polyangiitis / drug therapy*
Granulomatosis with Polyangiitis / immunology
Humans
Male
Middle Aged
Peroxidase / immunology*

Substances

Anti-Asthmatic Agents
Antibodies
Antibodies, Antineutrophil Cytoplasmic
Antibodies, Monoclonal, Humanized
benralizumab
Peroxidase